A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer by Takayuki Yoshino et al.
PHASE I STUDIES
A phase I study of intravenous aflibercept with FOLFIRI
in Japanese patients with previously treated metastatic
colorectal cancer
Takayuki Yoshino & Kentaro Yamazaki &
Kensei Yamaguchi & Toshihiko Doi & Narikazu Boku &
Nozomu Machida & Yusuke Onozawa &
Masako Asayama & Tadahiro Fujino & Atsushi Ohtsu
Received: 9 August 2012 /Accepted: 29 October 2012 /Published online: 20 November 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Summary Aflibercept, a recombinant fusion protein, is a
potent inhibitor of vascular endothelial growth factor
(VEGF)-A, VEGF-B, and the placental growth factor
(PlGF). The present study was an open-label, sequential-
cohort, dose-escalation trial of intravenous aflibercept admin-
istered every 2 weeks in combination with 5-fluorouracil,
levofolinate, and irinotecan (FOLFIRI) in patients with previ-
ously treated metastatic colorectal cancer (mCRC). We aimed
to assess the safety, dose-limiting toxicities (DLTs), pharma-
cokinetics, and preliminary efficacy of the combination ther-
apy to determine the recommended phase II dose (RPTD) for
Japanese patients. Two doses of aflibercept (2.0 and 4.0 mg/
kg) were set, and DLTs were evaluated in the first 2 cycles.
The subjects comprised 16 patients (n03 and 13 for 2.0 and
4.0 mg/kg aflibercept, respectively) who received a total of
149 cycles of aflibercept with FOLFIRI. No DLTs were ob-
served at both doses. The frequent adverse events encountered
were leukopenia, neutropenia, anemia, diarrhea, fatigue, de-
creased appetite, stomatitis, dysphonia, nausea, and epistaxis.
The most common grade 3/4 adverse events were neutropenia
for both doses and hypertension for the 4.0 mg/kg dose. Free
aflibercept exposure increased with the dose, whereas expo-
sure to VEGF-bound aflibercept remained similar at both
doses. The response rate and progression-free survival at
4.0 mg/kg was 8.3 % and 7.59 months, respectively. In con-
clusion, the combination of aflibercept and FOLFIRI was well
tolerated at both doses. The RPTD of aflibercept in combina-
tion with FOLFIRI for Japanese patients with mCRC was
determined to be 4.0 mg/kg every 2 weeks.
ClinicalTrials.gov identifier: NCT00921661
Keywords Aflibercept (VEGF trap) . Vascular endothelial
growth factor (VEGF) . FOLFIRI . Metastatic colorectal
cancer . Phase I study
Introduction
Angiogenesis is a physiological process generating new
blood vessels from preexisting vessels. Aberrant angiogen-
esis is associated with many pathological conditions, includ-
ing tumor growth and metastasis [1–5]. Vascular endothelial
growth factor (VEGF), a powerful mitogen for endothelial
cells, promotes the formation of new blood vessels and is
required for the growth of both normal and tumor tissues [1,
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6]. VEGF is one of the most potent angiogenic factors
involved in tumor-induced angiogenesis [7, 8]. Inhibition
of angiogenesis by agents that block VEGF has been vali-
dated as an effective antitumor therapy for the treatment of
multiple tumor types, including metastatic colorectal cancer
(mCRC) [9]. Aflibercept (also known as VEGF Trap) is a
recombinant fusion protein in which the extracellular
domains of human VEGF receptors (VEGFRs) 1 and 2 are
fused to the Fc portion of human immunoglobulin G1 [10].
Aflibercept binds with all isoforms of VEGF-A, with an
affinity higher than that of the endogenous receptor primar-
ily involved in angiogenesis (VEGFR-2). In addition, afli-
bercept binds to other VEGF family members, VEGF-B and
the placental growth factor (PlGF) [11]. PlGF has been
implicated in pathological angiogenesis, and its blocking
shows an antitumor effect in animal models [12, 13].
Preclinical studies have shown that aflibercept can effective-
ly suppress tumor vascularization and the growth of various
tumor types [10]. These results suggest that aflibercept may
offer an additional benefit in treating malignant disease.
Colorectal cancer (CRC) is the second most frequent
cancer and the second leading cause of cancer death in
developed countries [14]. Approximately 50 % of patients
with CRC develop metastatic disease [15]. Mortality from
CRC accounts for 12 % of all cancer deaths in Japan [16]. In
the United States, Europe, and Japan, the standard chemo-
therapies for mCRC in the first- and second-line settings are
FOLFOX (fluorouracil/leucovorin/oxaliplatin), CapeOX
(capecitabine/oxaliplatin), and FOLFIRI. The combinations
of molecular-targeted drugs, such as bevacizumab, cetuxi-
mab, and panitumumab, with the above mentioned standard
chemotherapy regimens have been demonstrated to offer
additional benefits; therefore, this approach is now incorpo-
rated into treatment guidelines. A recent multinational phase
III study showed that aflibercept in combination with
FOLFIRI as second-line treatment improved the survival
of patients with mCRC [17]. Aflibercept is the first
molecular-targeted drug to show a survival benefit in com-
bination with FOLFIRI in the second-line setting.
The present phase I study (ClinicalTrials.gov identifier:
NCT00921661) was conducted to assess the safety, dose-
limiting toxicities (DLTs), pharmacokinetics, and prelimi-
nary efficacy of intravenous aflibercept in combination with
FOLFIRI in previously treated patients with mCRC to de-
termine its RPTD for Japanese patients.
Materials and methods
Patient eligibility
Eligible patients were men or non-pregnant women aged
≥20 years, who had histologically or cytologically proven
metastatic unresectable colorectal adenocarcinomas and had
undergone at least one prior chemotherapy. All the eligible
patients provided written consent for participation in the
study before the initiation of any study-specific procedures.
Patients were excluded from the study if they met any of the
following criteria: anticancer therapy within 28 days before
the study; unresolved toxicity from prior anticancer therapy;
Eastern Cooperative Oncology Group (ECOG) performance
status >1; uncontrolled malignant ascites; central nervous
system involvement; severe heart disease (eg, myocardial
infarction, unstable angina, and New York Heart
Association [NYHA] class III or IV congestive heart fail-
ure); active human immunodeficiency virus (HIV) or hepa-
titis B or C infection; severe acute or chronic medical
condition(s); inadequate bone marrow function (neutrophil
count<1.5×109/L, platelet count<100×109/L, or hemoglo-
bin<9.0 g/dL); inadequate liver function (total bilirubin>
1.5×the upper limit of the normal range [ULN] and aspar-
tate aminotransferase or alanine aminotransferase>2.5×
ULN); inadequate renal function (creatinine>1.5×ULN or
creatinine clearance<60 mL/min); urine protein-creatinine
ratio >1 or urinary protein excretion >500 mg/24 h; uncon-
trolled hypertension of >150/100 mm Hg; uncontrolled
thromboembolic event, active bleeding, or coagulopathy;
and hypersensitivity to recombinant proteins or components
of FOLFIRI.
Study design
The present study was designed as an open-label,
sequential-cohort, dose-escalation, phase I trial conducted
at 3 clinical institutes in Japan. It was approved by the
institutional review board of all the participating institutes
and was conducted in accordance with the ethical principles
of the Declaration of Helsinki and the Japanese Good
Clinical Practice guidelines.
Drug dose and administration
This study consisted of 2 phases: the dose-escalation and
expansion phases. During the dose-escalation phase, afliber-
cept administration was started at 2.0 mg/kg (dose 1) and
then increased to 4.0 mg/kg (dose 2) in a stepwise manner.
Three to 6 patients initially received dose 1, and then an-
other 3 to 6 patients received dose 2 if no DLTwas observed
in the first 3 patients or if only 1 of the 6 patients experi-
enced DLT at dose 1. In the expansion phase, 10 additional
patients received the highest dose at which <33 % of the
patients developed DLTs in the dose-escalation phase. The
RPTD was determined on the basis of the presence of a DLT
incidence rate of <33 %, overall safety, and pharmacokinetic
analysis. Based on the RPTD of aflibercept for non-
Japanese patients indicated by a previous study, we used
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4.0 mg/kg once every 2 weeks as the optimum dose. The
same dose was also adopted for the global phase III study of
the FOLFIRI combination [17].
Aflibercept was administered by intravenous infusion in
combination with FOLFIRI every 2 weeks. On day 1 of
each cycle, the patients received the following drugs: afli-
bercept, intravenous infusion at dose 1 or 2 for 1 h; irinote-
can, 90-min infusion at 150 mg/m2 and co-administered
with levofolinate infusion (200 mg/m2) for 2 h; and 5-
fluorouracil (5-FU), bolus administration at 400 mg/m2 for
2–4 min, followed by a 46-h continuous infusion at
2400 mg/m2. Antiemetic premedication was administered
together with serotonin 5-HT3 receptor antagonist and dexa-
methasone before the initiation of aflibercept infusion.
Definition of DLT
A DLT was defined as any of the following toxicities occur-
ring during the first 2 cycles (cycles 1 and 2): grade 3 or 4
neutropenia complicated by fever (≥38.5 °C) or infection;
grade 4 neutropenia persisting for >7 days; grade 4 thrombo-
cytopenia or grade 3 thrombocytopenia complicated by hem-
orrhage; grade 4 non-hematologic toxicities; grade 3 non-
hematologic toxicities other than fatigue, anorexia, nausea,
vomiting, or hyponatremia; uncontrolled hypertension or pro-
teinuria; and symptomatic arterial thromboembolic events.
Safety and efficacy assessments
Safety was assessed by monitoring the incidence and severity
of the adverse events and abnormal laboratory results. The
adverse events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) ver. 3.0. Antitumor response was evaluated at
baseline and on day 14 of every 3 cycles according to the
Response Evaluation Criteria in Solid Tumors (RECIST) ver.
1.0 [18]. Response rate was defined as the proportion of
patients with complete response (CR) or partial response (PR)
in the analysis population. Disease control rate (DCR) was
defined as the proportion of patients with CR, PR, or stable
disease (SD) for at least 8 weeks from the initiation of the study
regimen. Progression-free survival (PFS) was defined as the
time from the registration to the date of disease progression
(documented tumor progression or clinical progression/symp-
tomatic deterioration) or death from any cause. The Kaplan-
Meier method was used to estimate the PFS. The 95 % confi-
dence interval (CI) for the median PFSwas calculated using the
method described by Brookmeyer and Crowley [19].
Pharmacokinetics and immunogenicity
Free and VEGF-bound aflibercept concentrations were mea-
sured using a specific enzyme-linked immunosorbent assay.
Blood samples were obtained at the following time points:
before and at 1, 3, 7, 23, 47, 167 (day 8), and 335 h (day 15)
after the end of aflibercept infusion in cycle 1; before
aflibercept infusion on day 1 of each cycle from cycle 2
onward; and 30 and 90 days after the end of the treatment
cycles. For plasma irinotecan concentrations, blood samples
were obtained before and at 1.5, 2.0, 4.5, and 23 h after the
initiation of irinotecan infusion in cycle 1. For plasma 5-FU
concentrations, blood samples were obtained before infu-
sion of aflibercept and at 2.5, 21, and 45 h after the bolus
administration of 5-FU in cycle 1. The pharmacokinetic
parameters were as follows: for free and VEGF-bound afli-
bercept, the parameters were concentration at trough
(Ctrough), maximum plasma concentration (Cmax), area under
the concentration time curve (AUC), clearance (CL), distri-
bution volume at steady state (Vss), terminal half-life (t1/2);
for irinotecan and its active metabolite SN-38, the parame-
ters were CL and AUC; and for 5-FU, the parameter was the
concentration at steady state during continuous infusion.
To examine the potential immunogenicity of aflibercept,
anti-aflibercept antibody levels were measured before infu-
sion on day 1 of each cycle, at the end of the treatment, and
at 90 d after the last study treatment.
Results
Patient characteristics
Sixteen patients were enrolled in this study, of whom 3
received dose 1 and 13 received dose 2. Ten patients in dose
2 were included for the expansion phase. The baseline
characteristics of all the patients are presented in Table 1.
The median patient age was 57 years. All the patients had an
ECOG performance status of 0 or 1, and the primary tumor
site was the colon or rectum (8 patients each). The patients
had previously undergone a median of 1 chemotherapy
regimen (range, 1–3), and all the 16 patients had been
treated with 5-FU; 15 (93.8 %), with oxaliplatin; 10
(62.5 %), with bevacizumab; and 3 (18.8 %), with irinote-
can. The data of all the 16 patients were included in the
safety, efficacy, and pharmacokinetic analyses. One patient
was excluded from DLT evaluation because the patient did
not receive cycle 2 of the aflibercept therapy due to consent
withdrawal not associated with adverse event.
Safety and tolerability
The median numbers of cycles administered were 6 (range,
3–9) and 10 (range, 1–23) and the total numbers of cycles
were 18 and 131 for doses 1 and 2, respectively. For all the 3
patients receiving dose 1 and 11 of the 13 patients receiving
dose 2, treatment was discontinued because of disease
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progression. With regard to the remaining 2 patients receiv-
ing dose 2, 1 requested discontinuation of the treatment in
order to receive an alternative treatment, whereas the other
patient was still receiving the treatment at the time of data
cutoff. The aflibercept dose was reduced once in 1 patient
receiving dose 2 at the discretion of the investigator owing
to grade 2 proteinuria. The treatment cycle was delayed for
>2 d in 80 % and 56 % of cycles at doses 1 and 2,
respectively. Accordingly, the mean cycle duration was 3.2
and 2.9 weeks, and the mean relative dose intensities for
aflibercept were 67 % and 73 % at doses 1 and 2,
respectively.
No DLTs were observed at both doses during the first
2 cycles. All the patients experienced at least one adverse
event. The incidence rates of the common adverse events are
summarized in Table 2. The frequently reported adverse
events at dose 1 were leukopenia, neutropenia, anemia,
diarrhea, nausea, vomiting, and fatigue; and those at dose
2 were leukopenia, neutropenia, anemia, diarrhea, fatigue,
decreased appetite, stomatitis, dysphonia, and nausea. Of
these, the most frequent grade 3/4 adverse event was neu-
tropenia at both doses. Serious adverse events were ob-
served after the DLT evaluation period in 2 patients at
dose 2. One patient experienced 2 episodes of grade 3
febrile neutropenia during cycles 3 and 10; and grade 3
anemia, grade 4 thrombocytopenia, and grade 3 dehydration
during cycle 10. All the adverse events were resolved,
except for anemia, which was observed to be improving at
the last follow-up examination. The other patient had a
grade 4 hepatic function abnormality due to disease
progression. There was no adverse event resulting in death
or treatment discontinuation. The most frequent adverse
event leading to dose reduction or cycle delay was neutro-
penia, which was observed in 100 % and 92.3 % of the
patients at doses 1 and 2, respectively. Toxicities commonly
associated with anti-angiogenesis agents, such as dysphonia,
epistaxis, hypertension, and proteinuria, were also observed.
The most frequent grade 3/4 adverse event associated with
anti-angiogenesis agents was hypertension, which was ob-
served only at dose 2.
Pharmacokinetics and immunogenicity
A graph of the mean plasma concentration plotted against
time for free and VEGF-bound aflibercept is presented in
Fig. 1. At both doses, the plasma concentration of free
aflibercept was highest on day 1 after infusion and de-
creased thereafter during the 2 weeks of cycle 1. The plasma
concentration of VEGF-bound aflibercept exhibited a grad-
ual increase. The plasma concentration of free aflibercept
was higher at dose 2 than at dose 1, whereas those of VEGF-
bound aflibercept were similar at both doses. The pharma-
cokinetic parameters of free and VEGF-bound aflibercept
are summarized in Table 3. The exposure to free aflibercept
increased with the dose, with the mean Cmax being 41.0 and
72.7 μg/mL and mean AUC being 140 and 269 μg·d/mL at
doses 1 and 2, respectively. In contrast, the exposure to
VEGF-bound aflibercept at dose 1 was similar to that at
dose 2, with the mean Cmax being 1.94 and 1.86 μg/mL and
mean AUC being 14.0 and 13.0 μg d/mL at the 2 respective




2 mg/kg (N03) 4 mg/kg (N013) ALL (N016)
Median age [range] (years) 59.0 [51–66] 55.0 [47–69] 57.0 [47–69]
Gender [n (%)]
Male 1 (33.3 %) 9 (69.2 %) 10 (62.5 %)
Female 2 (66.7 %) 4 (30.8 %) 6 (37.5 %)
Median weight [range] (kg) 51.5 [50.6–71.0] 62.9 [36.4-86.2] 61.3 [36.4–86.2]
ECOG PSa [n(%)]
0 2 (66.7 %) 7 (53.8 %) 9 (56.3 %)
1 1 (33.3 %) 6 (46.2 %) 7 (43.8 %)
Primary tumor site [n(%)]
Colon 2 (66.7 %) 6 (46.2 %) 8 (50.0 %)
Rectum 1 (33.3 %) 7 (53.8 %) 8 (50.0 %)
Median lines of prior chemotherapy [range] 2.0 [2, 3] 1.0 [1, 2] 1.0 [1–3]
Prior chemotherapy [n(%)]
5-FU 3 (100 %) 13 (100 %) 16 (100 %)
Irinotecan 2 (66.7 %) 1 (7.7 %) 3 (18.8 %)
Oxaliplatin 2 (66.7 %) 13 (100 %) 15 (93.8 %)
Bevacizumab 3 (100 %) 7 (53.8 %) 10 (62.5 %)
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doses. These findings suggest that the binding saturation of
endogenously produced VEGF to aflibercept was
achieved at both levels. The ratio of free aflibercept
concentration to VEGF-bound aflibercept concentration
at the trough (2 weeks after aflibercept administration)
was >1 throughout the treatment duration at dose 2
(Fig. 2), indicating that dose 2 (4.0 mg/kg) was suffi-
cient for providing a free aflibercept concentration in
excess of that of VEGF-bound aflibercept throughout
the treatment duration.
None of the 13 patients who were assessed for immuno-
genicity had positive results for anti-aflibercept antibodies.
No major allergic reactions were observed in this study.
Anti-tumor activity
Three and 12 patients receiving doses 1 and 2, respectively,
underwent tumor response evaluation according to the
RECIST criteria. The response rates were 0 % and 8.3 %
at doses 1 and 2, respectively, with 1 case of PR at dose 2.
The DCRs were 66.7 % and 75.0 % at doses 1 and 2,
respectively. The PFS at dose 2 was 7.59 months (95 %
CI, 2.33–9.59).
Discussion
To our knowledge, this is the first trial of the combination of
aflibercept and FOLFIRI in Japan. Our results showed that
Table 2 Incidence of common
all-causality adverse eventsa by
worst grade
aEvents listed are those occur-
ring in ≥4 patients at 4 mg/kg at
any grade.
bBased on laboratory data.
Preferred term Dose level
2 mg/kg (N03) 4 mg/kg (N013)
All grades n (%) Grades 3, 4 n (%) All grades n (%) Grades 3, 4 n (%)
Hematological toxicitiesb
Leukopenia 3 (100 %) 1 (33.3 %) 13 (100 %) 8 (61.5 %)
Neutropenia 3 (100 %) 3 (100 %) 12 (92.3 %) 10 (76.9 %)
Anemia 3 (100 %) 0 11 (84.6 %) 1 (7.7 %)
Thrombocytopenia 2 (66.7 %) 0 9 (69.2 %) 1 (7.7 %)
Non-hematological toxicities
Diarrhoea 3 (100 %) 0 12 (92.3 %) 1 (7.7 %)
Fatigue 3 (100 %) 0 12 (92.3 %) 0
Decreased appetite 2 (66.7 %) 0 12 (92.3 %) 0
Stomatitis 2 (66.7 %) 0 11 (84.6 %) 2 (15.4 %)
Dysphonia 2 (66.7 %) 0 11 (84.6 %) 0
Nausea 3 (100 %) 0 11 (84.6 %) 0
Epistaxis 1 (33.3 %) 0 10 (76.9 %) 0
Hypertension 0 0 8 (61.5 %) 4 (30.8 %)
Alopecia 2 (66.7 %) 0 8 (61.5 %) 0
Vomiting 3 (100 %) 0 7 (53.8 %) 0
Headache 1 (33.3 %) 0 6 (46.2 %) 0
Nasopharyngitis 1 (33.3 %) 0 5 (38.5 %) 0
Abdominal pain 1 (33.3 %) 0 5 (38.5 %) 0
Constipation 0 0 5 (38.5 %) 0
Gingivitis 0 0 5 (38.5 %) 0


















Free - 2 mg/kg (n = 3)
Free - 4 mg/kg (n = 13)
Bound - 2 mg/kg (n = 3)
Bound - 4 mg/kg (n = 13) 
Fig. 1 Mean plasma concentration versus time profiles of free and
VEGF-bound aflibercept (log scale) for cycle 1. After aflibercept
infusion, the plasma concentration of free aflibercept decreased, where-
as that of VEGF-bound aflibercept gradually increased throughout the
2-weekcycle. The plasma concentration of free aflibercept increased
with the dose, whereas that of VEGF-bound aflibercept was similar at
both doses
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the 2.0 and 4.0 mg/kg aflibercept doses were well tolerated
by the Japanese patients with mCRC. On the basis of the
acceptable overall safety profiles, pharmacokinetic analysis
results, and the absence of DLTs, 4.0 mg/kg, administered
every 2 weeks, was determined to be the RPTD of afliber-
cept in combination with FOLFIRI as second-line treatment
for the Japanese patients with mCRC. The same dose had
been determined as the RPTD in a previous phase I study of
aflibercept administered alone and that of the combination
of aflibercept with the irinotecan/5-FU/leucovorin (irinote-
can/LV5FU2) regimen in non-Japanese patients [20, 21]. A
previous multinational phase III study of aflibercept in com-
bination with FOLFIRI had also used the 4.0 mg/kg dose
[17]. The maximum tolerated dose could not be determined
in the present study, as doses higher than the recommended
dose for non-Japanese patients were not tested.
The frequently observed adverse events at both doses
included those related to bone marrow suppression (eg,
neutropenia), gastrointestinal symptoms (eg, diarrhea,
constipation, nausea, vomiting, stomatitis, abdominal
pain, and decreased appetite), and fatigue. These toxic-
ities are known to be associated with the FOLFIRI
backbone regimen. In addition, toxicities known to be
associated with VEGF pathway inhibition, such as dys-
phonia, hypertension, and epistaxis, were also frequently
observed.
The mean relative dose intensities for aflibercept were
67 % and 73 % at doses 1 and 2, respectively. The primary
reason for the decrease in dose intensities was the treatment
cycle delay of >2 d, which occurred in 80 % and 56 % of the
cycles at doses 1 and 2, respectively. The most frequent
adverse event leading to cycle delay was neutropenia.
Although neutropenia was frequently observed and often
resulted in cycle delays, the granulocyte colony-
stimulating factor was administered to only 2 patients re-
ceiving each dose, and all the patients eventually recovered
from neutropenia and continued the combination treat-
ment at the initial dose. Of the toxicities reported to be
associated with VEGF pathway inhibition, all the events
were of grade 2 or lower, except for hypertension. Four
patients (30.8 %) receiving dose 2 had grade 3/4 hyper-
tension but could continue the scheduled treatment with-
out aflibercept dose reduction. Proteinuria of grade 2 or
lower was observed in 3 patients (23.1 %) receiving
dose 2. None of the patients developed any other seri-
ous toxicities related to VEGF inhibition, such as arte-
rial or venous thrombotic/thromboembolic events,
gastrointestinal perforation, or reversible posterior leu-
koencephalopathy syndrome (RPLS).
Aflibercept forms inert complexes with VEGF derived
from normal and tumor tissues, and these complexes are
retained in the systemic circulation. VEGF-bound afliber-
cept is considered to indicate the amount of endogenous
VEGF produced in normal and tumor tissues. Free
Table 3 Plasma pharmacokinetic parameters of free and VEGF-bound aflibercept
Mean (CV%) PK parameters of Free and VEGF-bound aflibercept
Free Bound
Dose (mg/kg) N Cmax (μg/mL) AUC(0–14 days)
(μg∙day/mL)
CL (L/day) t1/2Z (day) Cmax (μg/mL) AUC(0–14 days)
(μg∙day/mL)
2 3 41.0 (18) 140 (17) 0.728 (24) 4.95 (28) 1.94 (12) 14.0 (NC)b
4 13 72.7 (28) 269 (36) 0.665 (19)a 5.59 (14)a 1.86 (14) 13.0 (2)c
Data are expressed as geometric mean, and percent coefficient of variance is expressed in parentheses.
aN08
bN02, NC 0 Not Calculable
cN03
Cycle





















Aflibercept 4 mg/kg 
Free/VEGF-bound = 1
Fig. 2 Ratio of free aflibercept concentration to VEGF-bound afliber-
cept concentration at the trough (2 weeks after aflibercept administra-
tion) across the treatment cycles for dose 2 (4.0 mg/kg). The mean±SD
value for each cycle is indicated. Note that the free/VEGF-bound
aflibercept concentration ratio was maintained at >1 (dotted line)
throughout the treatment duration
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aflibercept is available for binding with newly secreted
VEGF. The concentration ratio of free aflibercept to
VEGF-bound aflibercept at the trough was >1 at dose 2,
indicating that the free aflibercept concentration was in
excess of that of VEGF-bound aflibercept throughout the
treatment duration. Preclinical studies indicated that the
biological effects of aflibercept correlated with free afliber-
cept levels in excess of VEGF-bound aflibercept levels [22].
These pharmacokinetic findings suggest that the 4.0 mg/kg
dose provides a sufficient aflibercept concentration to effec-
tively block endogenous VEGF.
The preliminary efficacy analysis in this study showed 1
case (8.3 %) of PR at dose 2. For the 12 patients evaluated,
the DCR was relatively high (75.0 %), and the PFS was
7.59 months (95 % CI, 2.33–9.59) at dose 2. Although there
is potential for biases owing to the small sample size of
this study and heterogeneity in prior line(s) of chemo-
therapy, our results appear promising in light of the
published median PFS (range, 2.5–5.1 months) for
FOLFIRI as second-line treatment in patients with
mCRC [23–25].
In summary, the RPTD of aflibercept in combination with
FOLFIRI for the Japanese patients with mCRC was deter-
mined to be 4.0 mg/kg, administered every 2 weeks. The dose
was well tolerated and showed favorable pharmacokinetic
characteristics and preliminary efficacy. In a recent multina-
tional phase III study evaluating aflibercept plus FOLFIRI
versus placebo plus FOLFIRI in patients who had
mCRC and previously failed an oxaliplatin-based regi-
men, the primary end point of overall survival was
achieved. The aflibercept plus FOLFIRI combination
therapy also showed significant benefits in terms of
the secondary end points of PFS and objective response
rate. On the basis of the results of this phase III study
and our phase I study, further investigation is being
planned to evaluate the efficacy and safety of this
combination in Japanese mCRC patients.
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